Urgent Call for Affordable Breast Cancer Treatment in India

Access to Ribociclib: A Critical Issue

The issue of breast cancer treatment in India has gained significant attention following a petition that seeks affordable access to Ribociclib, a crucial medication. Despite being scheduled for final hearings 57 times since January 2023, the Kerala High Court has yet to address the matter. This situation has raised alarms about the impact of judicial delays on patients facing life-threatening conditions, where timely treatment is essential.

Initially filed in June 2022, the writ petition aimed to broaden access to Ribociclib, a targeted therapy for HR-positive, HER2-negative (Luminal A) breast cancer, which is among the most prevalent types. Unfortunately, the petitioner passed away during the early stages of the legal process. Acknowledging the public interest, the Kerala High Court has opted to continue the case on its own accord.

In response, the Working Group on Access to Medicines, which includes patient advocates, civil society members, and legal experts, has reached out to the Chief Justice of India, requesting an expedited hearing. They emphasize that prolonged delays in cases involving life-saving medications could have dire consequences for countless patients.

The Significance of Ribociclib for Patients

Why is Ribociclib important for breast cancer patients?

Ribociclib is classified as a CDK4/6 inhibitor and is typically prescribed in conjunction with hormone therapy for patients diagnosed with HR+/HER2- breast cancer. This medication plays a vital role in slowing the progression of cancer and enhancing survival rates. Additionally, it is utilized in early-stage patients to minimize the risk of recurrence.

However, the high cost of Ribociclib poses a significant barrier to access. The price exceeds Rupees 78,400 per month, while another targeted therapy, Abemaciclib, ranges from Rupees 47,700 to Rupees 95,500 monthly. For many families in India, these expenses make treatment unattainable.

Legal Efforts for Affordable Cancer Treatments

The legal battle for affordable cancer medicines

The petition calls for the government to issue a license under Section 100 of the Patents Act, which would enable generic manufacturers to produce Ribociclib for public distribution. Generic medications are often 90 to 95 percent less expensive than their patented counterparts, significantly enhancing affordability.

Despite acknowledging the effectiveness of Ribociclib, the government has refused to issue the license, claiming that breast cancer does not constitute a "national urgency." Advocates for patients have contested this viewpoint, asserting that access to essential medications is a fundamental right under Article 21 of the Constitution.

All parties involved, including the Union government, pharmaceutical companies, and the court-appointed amicus curiae, have submitted their responses, and the pleadings are complete. Yet, the case remains unheard on its merits.

Rising Breast Cancer Cases in India

India's growing breast cancer burden

This issue arises as breast cancer cases continue to escalate in India. The Global Cancer Observatory reported over 1.9 lakh new breast cancer cases and 98,300 deaths in a single year. Projections presented in Parliament in 2026 estimate around 2.4 lakh new cases, underscoring the increasing burden of this disease.

Health experts stress that early detection, prompt treatment, and consistent access to effective medications are crucial for improving survival rates.

The Importance of Timely Justice

Why is timely justice a matter of concern?

The passing of the original petitioner serves as a stark reminder of the human toll associated with delays in healthcare-related legal proceedings. While the ongoing case will address significant constitutional issues regarding access to essential medications, advocates argue that for many individuals with breast cancer, delayed justice equates to denied treatment.

As the demand for affordable cancer medications rises, the outcome of the Ribociclib case could influence future policies on access to patented drugs and how India navigates the balance between intellectual property rights and the fundamental right to life and healthcare.